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Abstract—Background: Few studies on cost of caring for patients with Alzheimer disease (AD) have simultaneously
considered multiple dimensions of disease costs and detailed clinical characteristics. Objective: To estimate empirically the
incremental effects of patients’ clinical characteristics on disease costs. Methods: Data are derived from the baseline visit
of 180 patients in the Predictors Study, a large, multicenter cohort of patients with probable AD followed from early stages
of the disease. All patients initially lived at home, in retirement homes, or in assisted living facilities. Costs of direct
medical care included hospitalizations, outpatient treatment and procedures, assistive devices, and medications. Costs of
direct nonmedical care included home health aides, respite care, and adult day care. Indirect costs were measured by
caregiving time. Patients’ clinical characteristics included cognitive status, functional capacity, psychotic symptoms,
behavioral problems, depressive symptoms, extrapyramidal signs, comorbidities, and duration of illness. Results: A 1-point
increase in the Blessed Dementia Rating Scale score was associated with a $1,411 increase in direct medical costs and a
$2,718 increase in unpaid caregiving costs. Direct medical costs also were $3,777 higher among subjects with depressive
symptoms than among those who were not depressed. Conclusions: Medical care costs and unpaid caregiving costs relate
differently to patients’ clinical characteristics. Poorer functional status is associated with higher medical care costs and
unpaid caregiving costs. Interventions may be particularly useful if targeted in the areas of basic and instrumental
activities of daily living.
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The high costs of caring for patients with Alzheimer
disease (AD) are well documented.1-13 Costs include
direct, indirect, and intangible costs.14,15 Direct costs
include payments for medical care and other goods
and services used because of the illness. These in-
clude multiple dimensions of medical care costs (e.g.,
nursing home care, medications, physician visits,
hospitalizations) and nonmedical care costs (e.g.,
home health aides, respite care, adult daycare). Indi-
rect costs are imputed values of resources lost due to
the illness, including premature deaths, patient and
caregiver lost productivity, and unpaid caregiving
time. Intangible costs are those related to pain and
suffering endured by the patients and families and
those related to deterioration of patient and care-
giver quality of life (QoL). Variations in costs of car-
ing for patients with AD have been explained by a
number of factors. Earlier studies used gross demen-
tia severity classification systems and estimated the
effect of disease severity on disease costs.6,7,9,14,16-19
More recently, several studies have examined the
effects on disease costs of patients’ comorbid medical
conditions,7,9 behavioral problems,4,19,20 and extrapy-
ramidal signs.13
Early work from the Predictors Study, a large,
multicenter cohort of patients with probable AD fol-
lowed from early stages of the disease, has developed
and validated algorithms to predict the length of
time until an individual patient required care equiv-
alent to nursing home care or died.21 The predictors
included sex, duration of illness, age at onset, modi-
fied Mini-Mental State Examination (mMMS) score,
and the presence or absence of extrapyramidal signs
or psychotic features. These clinical features were
chosen because they occur early in the disease and
can be assessed easily and reliably by a clinician in a
standard patient visit. Further work updating these
algorithms identified measures of functional capacity
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and a modified Charlson index of comorbidity as po-
tential predictor variables.22-24 In the current study,
we aim to extend our previous work and estimate
empirically effects of these patients’ clinical charac-
teristics on disease costs.
Methods. Sample. The sample is drawn from the Predictors 2
cohort and consisted of 204 patients with probable AD recruited in
1998 through 2004 from three sites: Columbia University Medical
Center, Johns Hopkins School of Medicine, and Massachusetts
General Hospital.23,25,26 The study was approved by the appropriate
local institutional review boards.
The inclusion and exclusion criteria are fully described else-
where.23,25,26 In brief, subjects met Diagnostic and Statistical Man-
ual of Mental Disorders (3rd rev. ed.) criteria for primary
degenerative dementia of the Alzheimer type and National Insti-
tute of Neurological Disorders and Stroke/Alzheimer’s Disease
and Related Disorders Association criteria for probable AD. En-
rollment required an mMMS score of !30, equivalent to a score of
approximately !16 on the Folstein Mini-Mental State Examina-
tion (MMSE).27,28 Because the patients are followed at academic
AD centers, they are well characterized with high degrees of cer-
tainty in their AD diagnosis. Overall, from both Predictors co-
horts, 109 patients have had autopsy examinations. Postmortem
diagnostic procedures have been completed for 96 patients, 96% of
whom had AD-type pathologic changes.
For the current study, we excluded 15 patients (7.3%) living in
nursing homes at baseline because patterns of care utilization and
cost differ substantially for nursing home patients.29 We further
excluded nine patients (4.4%) with missing cost data from our
analysis sample. The final analysis sample consisted of 180
patients.
Measures. The current study is based on data collected at the
initial visit, during which various sociodemographic and clinical
characteristics were assessed. Recruitment of patients in the Pre-
dictors Study began in 1998. For the analysis sample in this
study, initial baseline data were collected for 13.3% of patients in
1998, 8.3% in 1999, 24.3% in 2000, 26.0% in 2001, 15.5% in 2002,
11.1% in 2003, and 1.1% in 2004. Detailed information was col-
lected on patients’ healthcare utilization during the previous year.
Measures of healthcare utilization and cost. Patients and in-
formants reported utilization of seven domains of medical and
nonmedical care. Medical care included hospitalization, outpatient
treatment and procedures, assistive devices, and medications.
Nonmedical care included home health aides, respite care, and
adult day care. Patients and informants also reported on unpaid
caregiving time patients received. We annualized utilization rates
when domains of utilization were reported for three months (out-
patient medical test, treatments, and procedures; nonmedical
care; unpaid caregiving) and 6 months (medications).
Medical care. Hospitalizations. Patients and informants re-
ported number of hospital stays during the previous year and
reasons for each admission. We solicited consent to obtain pa-
tients’ hospital records as necessary. We used the 1999 data set of
HCUPnet, Healthcare Cost and Utilization Project sponsored by
the Agency for Healthcare Research and Quality (AHRQ), to cate-
gorize hospitalizations into the following 14 major diagnostic cat-
egories (MDCs): infectious and parasitic diseases; injuries,
poisons, and toxic effects of drugs; neoplasm; endocrine, nutri-
tional, and metabolic diseases; mental diseases and disorders; dis-
eases of the respiratory system; diseases of the circulatory system;
diseases of the musculoskeletal system and connective tissue; dis-
eases of the digestive system; diseases of the genitourinary sys-
tem; diseases of the skin, subcutaneous tissue, and breast;
diseases of blood, blood-forming organs, immunologic disorders;
diseases of the nervous system; and all other disease categories.30
When more than one diagnosis was reported, the hospitalization
was attributed to the diagnosis with the highest per-diem cost. No
additional cost was attributed. We found payment rates in the
northeast to be in the median of the price range, so we used the
overall national average rate per overnight hospital stay for each
MDC to compute the cost of hospitalizations.
Outpatient medical tests, treatments, and procedures. Pa-
tients and informants reported the type and number of outpatient
medical tests, treatments, and procedures patients received in the
previous 3 months. We used Current Procedure Terminology codes
from the American Medical Association to identify each item. We
used 1999 national average participating payment rates from
Clinical Diagnostic Laboratory Fee Schedule established by the
Centers for Medicare and Medicaid Services (CMS) to compute the
costs.31 When the payment rate for a particular item was not
listed, we obtained price data from various Web sites and used the
average price from different sources as the price for the item.
Assistive devices. Patients and informants reported the type
and number of assistive devices (e.g., walkers, grab bars) that
were purchased during the previous year. We used Healthcare
Common Procedure Coding System, established by CMS, to iden-
tify each item reported. We used 1999 payment rates for noninsti-
tutional providers to compute the costs of medical equipments.32
We examined overall ceiling and floor values, compared them with
the values for the three states in which the Predictors sites were
located, and chose to use the ceiling values as these correspond
most closely to values for the site’s states. When the payment rate
for a particular item was not listed, we obtained price data from
various Web sites and used the average price from different
sources as the price for the item.
Medications. Patients and informants reported detailed infor-
mation on the medications the patient took during the last 6
months, including the name of the drug, number of days taking
the drug, and number of pills per day. Prices for prescription
medications were taken from the 2000 Red Book.33 For over-the-
counter medications not listed in the Red Book, average price
across all brands were taken from www.cvs.com.
Nonmedical care. Patients and informants also reported utili-
zation of overnight respite care, adult daycare, and home health
aides in the previous 3 months. For adult daycare and home
health aides, patients and informants reported number of days,
average hours per day, and hourly cost for using the service.
Because prices of overnight respite care were not asked in the
questionnaire, we used national average cost of nursing home care
($130 per day) as its estimated unit price.4
Unpaid caregiving cost. Unpaid caregiving time was asked
for up to three caregivers (primary caregiver and two other care-
givers) on basic and instrumental activities of daily living (ADLs).
Basic ADLS (BADLs) included eating, dressing, and personal care
(e.g., bathing, toileting). Instrumental ADLs (IADLs) included
shopping, chores, personal business, and transportation. Hours of
unpaid care provided per day for each caregiving task were asked
in the following categories: 0, up to 3 hours, 3 to 6 hours, 6 to 9
hours, 9 to 12 hours, and more than 12 hours. We transformed the
categories into continuous values using the mean of each category
as the estimated hours of care provided. For subjects who reported
more than 12 hours per day for a particular type of task, we
top-coded the values to 12 hours. We followed the literature and
top-coded total hours of care provision for IADL and BADL tasks
at 16 hours to provide 8 hours of sleep for the caregivers.34 No
caregiver provided more than 16 hours of care per day at baseline.
We used the national average hourly earning for all private indus-
tries ($14.32) as the hourly wage rate to estimate unpaid caregiv-
ing costs.35
Clinical and sociodemographic characteristics. A number of
clinical features that occur early in the disease and can be as-
sessed easily and reliably by a clinician have been shown to be
associated with costs, mortality, or institutionalization among de-
mentia patients. We examined the association between the follow-
ing factors with health services utilization and costs.
Cognitive status. We used the MMSE to examine patients’
cognitive function.27 Higher scores indicate better cognitive status.
We categorized MMSE into two groups at a score of 20 because
it marked a transition from mild (MMSE ! 20) to moderate
(MMSE " 20) dementia.
Functional capacity. We used the Blessed Dementia Rating
Scale (BDRS) Parts I (IADLs) and II (BADLs) to assess patients’
functional capacity.36 This is a 17-point scale with higher scores
indicating worse functional status. As there are no established
cutoff points for this scale, we categorized the BDRS scores into
low- and high-functioning groups at the median score for ease of
presenting descriptive results.
Psychotic symptoms. Patients’ psychotic symptoms were
rated using the Columbia University Scale for Psychopathology in
Alzheimer’s Disease (CUSPAD), a semistructured interview ad-
ministered by a physician or a trained research technician. Most
CUSPAD items indicate presence or absence of a particular symp-
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tom. Reliability and validity of each symptom category of CUS-
PAD have been established in dementia populations with "
coefficients of 0.61 to 0.63.37 For delusions, the following categories
are included: general delusions (strange ideas, unusual beliefs),
paranoid (people are stealing things, unfaithful wife/husband, un-
founded suspicions), abandonment (accusing caregiver of plotting
to leave him/her), somatic (the patient has cancer or other physi-
cal illness), misidentification (people are in the house when no-
body is there, someone else is in the mirror, spouse/caregiver is an
imposter, the patient’s house is not his/her home, the characters
on television are real), and a miscellaneous category. Four catego-
ries of hallucinations were recorded: auditory, visual, tactile, and
olfactory. Patients were considered to have hallucinations if they
had hallucinations in any of the above four sensory modalities.
For illusions, the informant answered the question “Has the pa-
tient reported that one thing is something else (e.g., saying that a
pillow looks like a person or a light bulb looks like a fire start-
ing)?” We constructed a dichotomous variable to indicate the pres-
ence of any delusions, hallucinations, or illusions as evidence for
psychotic symptoms.
Behavioral problems. Patients’ behavior problems also were
measured using CUSPAD (" # 0.67).37 As in previous work,38 the
following five items were used to assess patients’ behavioral dis-
turbances: wandering away from home or caregiver, verbal out-
bursts, physical threats or violence, agitation or restlessness, and
sundowning (more confusion at night or during evening compared
with the day). We constructed a dichotomous variable to indicate
the presence of any of these five symptoms as evidence of behav-
ioral problems.
Depressive symptoms. Items for depressive symptoms also
were measured using CUSPAD (" # 0.73).37 These items included
depressed mood (sad, depressed, blue, down in the dumps), diffi-
culty sleeping, and change in appetite. As in previous work,39 we
constructed a dichotomous variable indicating patients having de-
pressive symptoms to be those reporting depressed mood and hav-
ing either difficulty sleeping or change in appetite.
Extrapyramidal signs. Extrapyramidal signs (EPSs) were as-
sessed by trained examiners using a modified Unified Parkinson’s
Disease Rating Scale (UPDRS) that has good interrater reliability
properties in dementia populations.40,41 The following 11 items
were rated on a Likert scale of 0 to 4 (with 0 being normal and 4
indicating maximum impairment): speech, facial expression,
tremor at rest, neck rigidity, right arm rigidity, left arm rigidity,
right leg rigidity, left leg rigidity, posture, gait, and bradykinesia.
In accordance with our previous work,23 we constructed a dichoto-
mous indicator for the presence of EPS if any item was rated 2 or
higher. The reasons for this cutoff are as follows: 1) We previously
demonstrated good interrater reliability for at least mild to mod-
erate severity (score of 2 or more indicating mild severity),40 and 2)
this level of severity is also more likely to be noted by the average
clinician.
Comorbid conditions. We used patients’ medical histories to
construct a modified version of the Charlson index of
comorbidity.22-24 Comorbid conditions included items for myocar-
dial infarct, congestive heart failure, peripheral vascular disease,
hypertension, chronic obstructive pulmonary disease, arthritis,
gastrointestinal diseases, mild liver disease, diabetes, chronic re-
nal disease, and systemic malignancy. No patients reported clini-
cal strokes, metastatic tumors, or AIDS at baseline.
Duration of illness. A neurologist estimated the disease dura-
tion based on interviews with the patient and informant.
Sociodemographic characteristics. We included in our analy-
sis a number of sociodemographic characteristics of the patients
including age, gender, education, and marital status.
Analysis. We compared the characteristics of patients who
were excluded from the analysis with those included in the study
and compared patients’ sociodemographic characteristics across
sites. Because utilization rates of nonmedical care (home health
aides, respite care, and adult day care) are relatively low, we
combined them into one category in the analyses. We compared
utilization rates and costs for each domain of medical care, non-
medical care, and unpaid care by the following patient clinical
characteristics: psychotic symptoms, EPSs, depressive symptoms,
behavioral problems, functional status, cognition, and comorbid
conditions. For bivariate analyses, we categorized these clinical
variables into presence or absence of symptoms or high and low
groups. Group comparisons of categorical variables (e.g., utiliza-
tion) were performed using $2 tests, and comparisons of continu-
ous variables (e.g., costs) were performed using nonparametric
Wilcoxon rank sum test. We chose the Wilcoxon rank sum test
over the Student t test because the cost variables are highly
skewed. All cost values are adjusted to constant 2004 dollars
using the medical care component of the Consumer Price Index.35
We hypothesized that direct and indirect costs were differen-
tially associated with different clinical characteristics. We esti-
mated separate equations for total medical costs and indirect costs
in the previous year using multivariate methods. Because cost
data are highly skewed, results from usual estimation methods
(e.g., ordinary least squares [OLS]) will be biased. We examined
the appropriateness of distributional family and link functions
using the modified Park test42 and chose generalized linear models
(GLM) with % family and log link as our estimation method. A
competing model for cost estimation is the OLS regression on
log-transformed dependent variable with retransformation of the
estimates to the natural scale using the Duan smearing estima-
tor.43 However, evidence in the recent literature suggests a num-
ber of problems related to retransformation.42,44 In particular,
retransformation may lead to biased results if data are heterosce-
dastic in a continuous variable or multiple covariates, which often
occurs in cost data. We chose the GLM model over the log OLS
model because accumulating evidence in the literature suggests
that the performance of GLM models may be superior in terms of
providing robust, unbiased estimation results.45,46 We tested the
goodness of fit of our estimation models using modified Hosmer–
Lemeshow test.47 If the link function is correct and the specifica-
tion of the covariates are appropriate, then Hosmer–Lemeshow
test statistic should not be significantly different from zero. Be-
cause only 17% of the subjects (n # 31) used nonmedical care, we
did not estimate a cost equation for nonmedical care. We included
all of the identified clinical characteristics in the estimation model
to examine the marginal effect of each variable on the dependent
variables. MMSE and BDRS scores were entered as continuous
scale scores. Psychotic symptoms, behavioral problems, and de-
pressive symptoms, all of which were measured in the CUSPAD,
were entered as dichotomous variables because previous research
report that it is difficult to rank CUSPAD scores and it is best to
construct dichotomous variables from it.24,38 All analyses were per-
formed using Stata 8.0.48
Results. Sociodemographic and clinical characteristics.
Compared with others, patients living in nursing homes
were older, more likely to be women, and less likely to be
married (results not shown). They also had lower MMSE
scores and more comorbid conditions. The nine patients
who had missing cost information were not significantly
different in sociodemographic characteristics and disease
severity from patients with complete cost information.
Sociodemographic and clinical characteristics of the
subjects at baseline are presented in table 1. The average
patient was 75.4 years old. Slightly over half were men
(56.1%). The patients in the sample were largely non-
Hispanic white (93.3%), well educated (with an average of
14.5 years of schooling), and either married (65.6%) or
widowed (26.7%). There were no differences in subjects’
sociodemographic characteristics across sites.
Because of the study inclusion criteria, patients were at
early stages of AD. Most patients (95%) were mildly de-
mented with a Clinical Dementia Rating Scale (CDR) score
of 1, and 5% were moderated demented with a CDR score
of 2.49 Neurologists’ estimate of average duration of illness
was 4.2 years (SD # 2.2); 90% of the patients had symp-
toms for 6 or fewer years. Mean MMSE score at baseline
was 22.1 (SD # 3.8), and mean BDRS score was 3.5 (SD #
2.3). Whereas almost all patients had some IADL limita-
tions, two-thirds (64%) were not limited in BADLs. Behav-
ioral problems (42.2%) and psychotic symptoms (32%) were
common by CUSPAD ratings. About 20% had depressive
symptoms, and 13.3% exhibited EPSs. On average, pa-
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tients had fewer than one comorbid condition (mean # 0.7,
SD # 0.8); half of the patients did not have any comorbid
conditions.
Utilization and annual per-capita costs. Table 2 pre-
sents data on utilization rates for each component of med-
ical care, nonmedical care, and unpaid care by patients’
clinical characteristics. Because of high rates of medication
use (96.1%), all patients used some type of medical care
during the previous year. On average, 21.7% reported be-
ing hospitalized; 73.3% reported receiving outpatient med-
ical tests, treatments, or procedures; and 41.7% reported
using assistive devices; 17.2% used some type of nonmedi-
cal care, mostly home health aides (11.1%) or adult day
care (7.2%). Almost all patients (92.8%) received unpaid
care.
In general, utilization rates were higher among patients
with more severe clinical features. Because of almost uni-
versal use, utilization of medications and unpaid care were
not significantly different by any of the clinical character-
istics. Patients who were more functionally dependent
used significantly more services in all other types of ser-
vices. Those with worse cognition were more likely to use
assistive devices and nonmedical care. Compared with
those without any symptoms, patients exhibiting psychotic
symptoms were significantly more likely to use outpatient
treatment and tests, assistive devices, and nonmedical
care. Patients with EPS and those with behavioral prob-
lems were significantly more likely to use assistive devices
and nonmedical care than those without EPS or behavioral
problems.
Translating utilization into the costs, we estimated that
average annual cost per patient was $7,918 for medical
care and $1,842 for nonmedical care. The largest compo-
nents of medical care costs were hospitalizations ($3,264,
41% of total costs) and medications ($2,855, 36% of total
costs). Costs of outpatient treatments, tests, and proce-
dures ($1,655) also were substantial, accounting for ap-
proximately 21% of total medical care costs. Patients
received an average of 23 hours of unpaid care per week.
We estimated annual unpaid costs to be $15,906, almost
twice the cost of all medical care and nonmedical care costs
combined.
Similar to utilization rates, costs were almost univer-
sally higher among patients with worse clinical features.
Unadjusted differences in total medical costs between pa-
tients with worse and better clinical features were $2,657
for psychotic symptoms, $4,767 for depressive symptoms,
$3,352 for functional dependence, and $3,209 for comorbid
conditions. Unadjusted differences in unpaid caregiving
costs between patients with worse and better clinical fea-
tures were $2,589 for psychotic symptoms, $3,824 for be-
havioral problems, and $9,579 for functional dependence.
Adjusted medical and unpaid caregiving costs. Table
3 presents regression results of total medical costs and
unpaid costs on patients’ clinical and sociodemographic
characteristics. Because costs were highly skewed (2.64 for
total direct medical care, 4.67 for total direct nonmedical
care, and 1.85 for unpaid caregiving cost), we chose GLM
as our estimation method. The Hosmer–Lemeshow test
found no evidence of systematic misfitting in either esti-
mation equation. Subjects’ functional status and depres-
sive symptoms were significantly associated with medical
care costs. Controlling for other variables, a 1-point in-
crease in the BDRS score increased medical cost by $1,411.
Medical costs were $3,777 higher among subjects with de-
pressive symptoms than those who were not depressed.
Although only marginally significant, presence of psychotic
symptoms, number of comorbidities, duration of disease,
and older age also were associated with total medical costs.
There were no gender or site differences in total medical
costs. On the other hand, the only variable that was signif-
icantly associated with unpaid caregiving costs was sub-
jects’ functional status. A 1-point increase in the BDRS
scores increased unpaid caregiving costs by $2,718.
Discussion. In this study, we estimated empiri-
cally the marginal effects of various clinical charac-
teristics on disease costs during early stages of AD.
At baseline, the patients in the sample were mildly
impaired in cognition (mMMS score ! 30), few pa-
tients had more than one psychotic or depressive
symptom, and EPS prevalence was low. Results
show that medical care costs and unpaid caregiving
costs respond differently with patients’ clinical char-
acteristics. Patients’ functional status, depressive
symptoms, psychotic symptoms, comorbidities, dura-
tion of symptoms, and age were strongly associated
with medical care costs. Contrary to medical care
costs and consistent with the literature,19,50 we found
Table 1 Baseline sociodemographic and clinical characteristics of
patients (n # 180)
Age, mean (SD); y 75.4 (7.6)
Younger than age 65, n (%) 16 (8.9)
Age 65–74, n (%) 54 (30.0)
Age 75–84, n (%) 89 (49.4)
Age 85 or older, n (%) 21 (11.7)
Men/women, n (%) 101 (56.1)/79 (43.9)
Race
White, n (%) 168 (93.3)
Black, n (%) 10 (5.6)
Other, n (%) 2 (1.1)
Years of schooling completed, mean (SD) 14.5 (3.2)
Marital status
Married, n (%) 116 (66.1)
Widowed, n (%) 47 (26.1)
Other, n (%) 14 (7.7)
MMSE, mean (SD) 22.1 (3.8)
BDRS, mean (SD) 3.5 (2.3)
EPS, n (%) 24 (13.3)
Psychotic symptoms, n (%) 59 (32.8)
Behavioral problems, n (%) 78 (43.3)
Depressive symptoms, n (%) 36 (20.0)
Years since symptoms, mean (SD) 4.2 (2.2)
Comorbid conditions
None, n (%) 90 (50.0)
One, n (%) 60 (33.3)
Two or more, n (%) 30 (16.7)
Site
Columbia, n (%) 88 (48.9)
Johns Hopkins, n (%) 48 (26.7)
Massachusetts General, n (%) 44 (24.4)
MMSE # Mini-Mental State Examination (range # 0–30); BDRS #
Blessed Dementia Rating Scale (range # 0–17); EPS # extrapyramidal
signs.
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that variations in unpaid caregiving cost were only
significantly associated with patients’ functional sta-
tus. Partially owing to the fact that patients were at
early stages of AD at baseline, we were unable to
estimate the effects of the severity of clinical fea-
tures on costs. Several other variables also may be
importantly associated with indirect costs. For exam-
ples, behavioral problems and number of comorbid
conditions were associated with higher indirect costs;
and the presence of EPS was surprisingly associated
with lower indirect costs. However, possibly because
of the small sample size, the standard errors of these
estimates were so large that the coefficients were not
statistically significant.
It should be noted that the effects of cognitive
decline may be underestimated in our models be-
cause cognition, functional status, and depression
may be correlated, and cognitive impairment may
lead to functional decline and depression. We exam-
ined the correlation between these factors. Patients’
MMSE and BDRS scores were highly correlated (r #
&0.3427, p ' 0.001), but patients’ MMSE scores
were not significantly different between those with
depressive symptoms (mean MMSE # 40.4, SD #
7.0) and those without (mean MMSE # 42.3, SD #
6.8). To address the issue of potential underestima-
tion of the effects of cognition, we re-estimated our
models by entering patients’ MMSE scores alone. Re-
sults show that MMSE scores were not significant in
either equation. Perhaps because the patients in our
sample were in the early stages of AD, MMSE scores
were not significantly associated with costs. How-
ever, the conclusion that functional status is more
important than cognition should not be drawn from
these analyses. In future studies, we will examine
the effect of cognitive decline on function and costs
using longitudinal data.
We based the cost estimates on payment rates
from a number of sources (CMS, AHRQ, the Red
Book). No cost-to-charge ratios were therefore ap-
plied. We did not find a national average cost for
overnight respite care in the literature and used the
cost of nursing home care ($130 per day) as its esti-
mate.4 We also considered using the cost for assisted
living care ($108 per day) as an alternative estimate
for the cost of respite care.4 Because so few patients
used respite care, our estimates of nonmedical care
costs would not be substantially changed. Large pro-
portion of service utilization occurred during 1999
through 2001. We used 2000 price data and adjusted
cost values to constant 2004 dollars so our cost esti-
mates would more closely reflect the time of utiliza-











All sample 96.1 21.7 73.3 41.7 17.2 92.8
Psychotic symptoms
Not present 95.1 18.7 67.5‡ 35.8† 10.6‡ 91.9
Present 98.2 28.1 86.0 54.4 31.6 94.7
Extrapyramidal signs
Not present 96.2 20.5 71.8 38.5† 15.4* 92.9
Present 95.8 29.2 83.3 62.5 29.2 91.7
Depressive symptoms
Not present 95.8 19.4 71.5 39.6 16.7 93.8
Present 97.2 30.6 80.6 50.0 19.4 88.9
Behavioral problems
Not present 94.2 19.2 70.2 32.7‡ 12.5† 94.2
Present 98.7 25.0 77.6 53.9 23.7 90.8
BDRS
Higher function 95.1 15.7‡ 65.7‡ 27.5‡ 6.9‡ 92.2
Lower function 97.4 29.5 83.3 60.3 30.8 93.6
MMSE
"20 (moderate) 97.5 20.8 69.2* 38.3 11.5* 82.5
!20 (mild) 93.3 23.3 85.0 48.3 21.7 93.3
Years since symptoms began
"4 97.2 22.2 77.8 45.4 16.7 93.5
!4 94.4 20.8 66.7 36.1 18.1 91.7
No. of comorbidities
0 97.8 17.8† 70.0 46.7 12.2 86.7
1 93.4 19.7 80.3 32.8 21.3 100.0
2 or more 96.6 37.9 69.0 44.8 24.1 96.6
* p ' 0.10, † p ' 0.05, ‡ p ' 0.01 from $2 tests.
BDRS # Blessed Dementia Rating Scale (range # 0–17); MMSE # Mini-Mental State Examination (range # 0–30).
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tion. We recognize that the validity of these
estimates depends on the generalizability of the data
and the accuracy of the unit prices, and actual re-
source costs may differ from our estimates. However,
estimating the actual cost of care for each medical
center would be costly and subject to measurement
error as well. Furthermore, the actual cost would be
specific to the site, whereas the payment schedules
we used are reasonable estimates of what would be
paid in general. The annualization procedure we
used should not bias the multivariate findings, be-
cause it simply introduces a constant to the depen-
dent variables.
Although providing comprehensive estimates of
direct and indirect costs of caring for patients in
early stages of AD is not a primary goal of this study,
our results indicate the validity of the data collection
process used in the Predictors Study. Using our
gross costing method, we estimate that annual cost
per patient amounted to $17,232 for unpaid care and
$7,929 for direct medical care. The largest compo-
nents of medical care costs were hospitalizations
($3,310, 41.7%) and medications ($2,853, 36.0%). For
this group of mildly demented patients, nonmedical
care costs ($1,604 per year) were comparatively
smaller in magnitude. The magnitude of these re-
sults is consistent with existing studies and again
shows that unpaid caregiving costs are more than
twice that of total direct costs among AD patients
living in the communities.17,51
Our multivariate results help provide information
for deriving estimates of potential cost savings if in-
terventions that aim to improve patients’ functioning
are developed. Results suggest that small differences
in functioning may be associated with large differ-
ences in medical care costs and unpaid caregiving
costs. An intervention that improves BDRS score
among AD patients could be expected to yield aver-
age savings of $1,411 per year in medical costs and
$2,718 in unpaid caregiving costs. As a secondary
analysis, we tested our models using BDRS factors
instead of the total score to examine which specific
domains were most sensitive to costs. As a group, the
BDRS factors were significantly associated with both
higher medical costs and higher unpaid caregiving
costs. In particular, the IADL factor was associated
with indirect cost and the BADL factor was associ-
ated with higher medical costs. Interventions may be
particularly useful if improvements are in the areas
of IADLs and BADLs.
It is notable that the potential cost savings we
estimated are generated from a sample of mildly de-
mented patients. An earlier study found that al-
though most cost savings may not be realized
immediately, a delay in disease progression for pa-
tients at early stages of the disease would yield
greater cost savings than the same delay experi-
enced by patients at later disease stages.52 Because
subjects have been followed closely in our study, our
future work will address issues of lifetime cost sav-
ings more appropriately by using longitudinal
analyses.
Our study has several limitations. First, results
reported here are from a cross-sectional analysis. An
important limitation of the cross-sectional design is
that the relationships reported can only be inter-
preted as associations. Although certain clinical fea-
tures can lead to higher costs, it also is possible that
low spending on healthcare indicates insufficient
medical care and results in poor health. Future work
Table 3 Generalized linear models of baseline medical care and indirect care costs (n # 180)
Variables Direct medical care, coefficient (SE) Indirect care, coefficient (SE)
Psychotic symptoms (1 # present, 0 # absent) 2,477* (1,436) &733 (3,467)
Extrapyramidal signs (1 # present, 0 # absent) &321 (2,057) &3,761 (4,619)
Depressive symptoms (1 # present, 0 # absent) 3,777† (1,687) &157 (3,777)
Behavior problems (1 # present, 0 # absent) 112 (651) 1,389 (1,539)
BDRS score 1,411‡ (542) 2,718† (1,354)
No. of comorbidities 1,741* (950) 2,800 (2,116)
MMSE score 56 (211) &354 (443)
Years since symptoms began "4 (1 # yes, 0 # no) 2,305* (1,297) 1,966 (3,178)
Age 65 or older (1 # yes, 0 # no) 4,076* (2,210) 508 (5,101)
Women (1 # yes, 0 # no) &1,990 (1,320) &14 (3,130)
Site (reference # Columbia)
Johns Hopkins &1,564 (1,666) &2,860 (3,754)
Massachusetts General &1,024 (1,595) &7,621 (3,678)
Constant 20,856‡ (5,407) 23,946† (11,571)
Log likelihood &1,767.256 &1,897.378
Akaike Information Criterion 19.891 21.345
Bayesian Information Criterion &721.942 &771.826
Pregibon link test ($21), p value 0.163 0.505
Hosmer–Lemeshow test (F10,170), p value 0.523 0.540
* p ' 0.10, † p ' 0.05, ‡ p ' 0.01.
BDRS # Blessed Dementia Rating Scale (range # 0–17); MMSE # Mini-Mental State Examination (range # 0–30).
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using longitudinal data is necessary to determine if
the relationships reported in this study are consis-
tent over time.
Second, although our estimate of indirect costs al-
ready are substantial, it is important to note that we
only included the cost of caregivers’ time. Indirect
costs also may include those related to caregivers’
lost productivity, and reduced hours of work and in-
come. However, reductions in work hours due to
caregiving and hours spent on caregiving may over-
lap and lead to possible double counting of caregiving
costs. In this sample, fewer than 15% of the caregiv-
ers who worked reported reducing work hours be-
cause of caregiving responsibilities. Among these
caregivers, average work hour reduction was 2.3
hours per week. In this sample and at the early
stages of the disease, costs from reduced work hours
are therefore relatively minor. It also is important to
consider other intangible costs such as patient and
caregiver QoL. Although the QoL questions were in-
cluded in the study, valuation of such costs is diffi-
cult and beyond the scope of this study. In this study,
we used national average hourly earning for all pri-
vate industries as the hourly wage rate to estimate
the cost of caregivers’ time. As market wages may
not accurately reflect caregivers’ opportunity cost of
time, another method is to estimate the caregivers’
wage rate in computing time cost. Possible differ-
ences in results in using these methods have impli-
cations for comparing direct and indirect costs of
care. An earlier study on unpaid dementia caregiving
costs suggests that results from using these two
methods are similar.9
Data on patients’ healthcare utilization from this
study were reported by patients and informants.
Most of the informants were the patients’ primary
caregivers. Studies have shown that caregivers are
able to accurately report medical information of their
care recipients.53,54 There is no reason to believe our
sample will be systematically different. Patients
were selected from tertiary care university hospitals
and specialized diagnostic and treatment centers
and thus represent a nonrandom sample of those
affected by AD in the population. The patients in our
sample also were predominantly white and highly
educated. Caution is needed in generalizing the re-
sults of this study to patients with lower levels of
education and income and to community AD pa-
tients. Future research will need to examine the re-
lationship between costs and the potential variables
in samples that are more representative of the gen-
eral population. However, because patients were
drawn from multiple locations, the generalizability
of our findings is enhanced.
Finally, our study is limited by the relatively
small sample size. This points to the common
tradeoff between national representativeness and re-
finement of diagnosis and richness of clinical vari-
ables in smaller studies. Studies from large national
surveys typically do not have detailed information on
patients’ clinical characteristics. Studies that rely on
administrative databases (e.g., claims data) typically
find only patients that are at more severe stages of
the disease. Our data, though smaller in sample size,
capture patients at early stages of the disease and
have a substantially richer set of accurately assessed
clinical characteristics. A major contribution of the
current analyses lies in the careful diagnosis and
clinical follow-up that patients received. Clinical di-
agnoses took place in university hospitals with spe-
cific expertise in dementia and were based on
uniform application of widely accepted criteria via
consensus diagnostic conference procedures. The ac-
curacy of the AD diagnoses has been confirmed in a
high proportion (96%) of those who have come to
postmortem evaluation.23 Finally, confidence in clini-
cal characteristics is further increased because they
were ascertained and coded in a standardized fash-
ion using validated scales rather than clinical assess-
ments. With the detailed data on clinical
characteristics, our study complements those using
large national datasets.
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